Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Heart failure in Europe : Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry
ID
Lund, Lars H.
(
Author
),
ID
Lainščak, Mitja
(
Author
), et al.
PDF - Presentation file,
Download
(1,04 MB)
MD5: 01BDAC8D8A6F16DE14DFD86400F1F843
URL - Source URL, Visit
https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3445
Image galllery
Abstract
Aims: We analysed baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry. Methods and results: Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62-79], 36% women) or outpatient visit for HF (61%, age 66 [58-75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC-affiliated countries. With AHF, 97% were hospitalized, 2.2% received intravenous treatment in the emergency department, and 0.9% received intravenous treatment in an outpatient clinic. AHF was seen by most by a general cardiologist (51%) and outpatient HF most by a HF specialist (48%). A majority had been hospitalized for HF before, but 26% of AHF and 6.1% of outpatient HF had de novo HF. Baseline use, initiation and discontinuation of GDMT varied according to AHF versus outpatient HF, de novo versus pre-existing HF, and by ejection fraction. After the AHF event or outpatient HF visit, use of any renin-angiotensin system inhibitor, angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist and loop diuretics was 89%, 29%, 92%, 78%, and 85% in HFrEF; 89%, 9.7%, 90%, 64%, and 81% in HFmrEF; and 77%, 3.1%, 80%, 48%, and 80% in HFpEF. Conclusion: Use and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC-affiliated countries.
Language:
English
Keywords:
ejection fraction
,
guideline-directed medical therapy
,
heart failure
,
implementation
,
quality of care
,
registry
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 2487-2501
Numbering:
Vol. 26, iss. 12
PID:
20.500.12556/RUL-182442
UDC:
616.1
ISSN on article:
1388-9842
DOI:
10.1002/ejhf.3445
COBISS.SI-ID:
225964035
Publication date in RUL:
12.05.2026
Views:
380
Downloads:
190
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
European journal of heart failure
Shortened title:
Eur. j. heart fail.
Publisher:
Wiley, European Society of Cardiology
ISSN:
1388-9842
COBISS.SI-ID:
1217301
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Secondary language
Language:
Slovenian
Keywords:
iztisni delež
,
s smernicami usmerjena medicinska terapija
,
srčno popuščanje
,
implementacija
,
kakovost oskrbe
,
register
Projects
Funder:
Abbot Vascular Int.
Funder:
Amgen Cardiovascular
Funder:
AstraZeneca AB
Funder:
Bayer AG
Funder:
Boehringer Ingelheim
Funder:
Bristol Myers Squibb
Funder:
Daichii Sankyo Europe GmbH
Funder:
Edwards Lifesciences
Funder:
Novartis Pharma AG
Funder:
Servier
Funder:
Vifor
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back